Arcus Biosciences, Inc. (RCUS) Stock Forecast
RCUS analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 14 analysts
- Price target
- $40.77 average of analyst targets
- Upside to target
- +84.3% from the latest close
- Next earnings
- October 27, 2026 EPS estimate $-0.93
- 52-week range
- $16.78 – $31.57
RCUS analyst ratings
14 analystsNumber of analysts at each rating.
RCUS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RCUS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.89 | −$1.00 | −$0.84 | −$1.27 | +29.7% | 9 |
| Current fiscal year (2026) | −$3.52 | −$4.35 | −$3.10 | −$3.29 | −6.9% | 9 |
| Next fiscal year (2027) | −$3.12 | −$4.50 | −$2.16 | −$3.52 | +11.2% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RCUS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $9.9M | $5.0M | $21.0M | −61.8% | 10 |
| Current fiscal year (2026) | $74.3M | $58.0M | $97.9M | −69.9% | 13 |
| Next fiscal year (2027) | $60.9M | $0 | $163.0M | −18.1% | 11 |
RCUS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RCUS revenue: reported and forecast
RCUS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.83 | −$0.91 | −$0.88 | −$0.86 | −$0.89 | +8.1% | 4 up · 2 down |
| Current fiscal year (2026) | −$3.48 | −$3.65 | −$3.53 | −$3.48 | −$3.52 | +1.0% | 3 up · 3 down |
| Next fiscal year (2027) | −$3.10 | −$3.25 | −$3.34 | −$3.27 | −$3.12 | +0.7% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RCUS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RCUS beat in 9 of 12.
What analysts expect from RCUS
14 analysts cover Arcus Biosciences; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $40.77, 84.3% above the latest close of $22.12. Analysts expect earnings of −$3.52 per share for 2026, −6.9% from a year earlier. For 2027 the average estimate is −$3.12 per share on revenue of $60.9 million. Arcus Biosciences beat the EPS estimate in 9 of the last 12 quarters.
Related: RCUS income statement, RCUS key metrics, RCUS chart. See the RCUS stock overview for the latest quote and news.
RCUS forecast FAQ
What is Arcus Biosciences's price target?
The average analyst price target for Arcus Biosciences is $40.77, 84.3% above the latest close of $22.12.
Is Arcus Biosciences a buy, hold or sell?
Of 14 analysts covering Arcus Biosciences, 11 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Arcus Biosciences's EPS forecast?
Analysts forecast −$3.52 per share for 2026 (range −$4.35 to −$3.10); for 2027 the estimate is −$3.12.
What is Arcus Biosciences's revenue forecast?
The average revenue estimate for 2026 is $74.3 million, growth of −69.9%; for 2027 it is $60.9 million.
When does Arcus Biosciences report earnings?
Arcus Biosciences is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes; the EPS estimate is $-0.93.
Does Arcus Biosciences usually beat earnings estimates?
Arcus Biosciences reported EPS at or above the analyst estimate in 9 of the last 12 quarters.